An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression.

Wyszynski, A; Hong, CC; Lam, K; Michailidou, K; Lytle, C; Yao, S; Zhang, Y; Bolla, MK; Wang, Q; Dennis, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Peto, J; Dos-Santos-Silva, I; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Nordestgaard, BG; González-Neira, A; Benitez, J; Neuhausen, SL; Brenner, H; Dieffenbach, AK; Meindl, A; Schmutzler, RK; Brauch, H; GENICA Network, ; Nevanlinna, H; Khan, S; Matsuo, K; Ito, H; Dörk, T; Bogdanova, NV; Lindblom, A; Margolin, S; Mannermaa, A; Kosma, VM; kConFab Investigators, ; Australian Ovarian Cancer Study Group, ; Wu, AH; Van Den Berg, D; Lambrechts, D; Wildiers, H; Chang-Claude, J; Rudolph, A; Radice, P; Peterlongo, P; Couch, FJ; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Henderson, BE; Dumont, M; Teo, SH; Wong, TY; Kristensen, V; Zheng, W; Long, J; Winqvist, R; Pylkäs, K; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; García-Closas, M; Figueroa, J; Klevebring, D; Czene, K; Hooning, MJ; van den Ouweland, AM; Darabi, H; Shu, XO; Gao, YT; Cox, A; Blot, W; Signorello, LB; Shah, M; Kang, D; Choi, JY; Hartman, M; Miao, H; Hamann, U; Jakubowska, A; Lubinski, J; Sangrajrang, S; McKay, J; Toland, AE; Yannoukakos, D; Shen, CY; Wu, PE; Swerdlow, A; Orr, N; Simard, J; Pharoah, PD; Dunning, AM; Chenevix-Trench, G; Hall, P; Bandera, E; Amos, C; Ambrosone, C; Easton, DF; Cole, MD; (2016) An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human molecular genetics, 25 (17). pp. 3863-3876. ISSN 0964-6906 DOI:

Full text not available from this repository.


: Breast cancer is the most diagnosed malignancy and the second leading cause of cancer mortality in females. Previous association studies have identified variants on 2q35 associated with the risk of breast cancer. To identify functional susceptibility loci for breast cancer, we interrogated the 2q35 gene desert for chromatin architecture and functional variation correlated with gene expression. We report a novel intergenic breast cancer risk locus containing an enhancer copy number variation (enCNV; deletion) located approximately 400Kb upstream to IGFBP5, which overlaps an intergenic ERα-bound enhancer that loops to the IGFBP5 promoter. The enCNV is correlated with modified ERα binding and monoallelic-repression of IGFBP5 following oestrogen treatment. We investigated the association of enCNV genotype with breast cancer in 1,182 cases and 1,362 controls, and replicate our findings in an independent set of 62,533 cases and 60,966 controls from 41 case control studies and 11 GWAS. We report a dose-dependent inverse association of 2q35 enCNV genotype (percopy OR = 0.68 95%CI 0.55-0.83, P = 0.0002; replication OR = 0.77 95% CI 0.73-0.82, P = 2.1 × 10(-19)) and identify 13 additional linked variants (r(2 )&gt;( )0.8) in the 20Kb linkage block containing the enCNV (P = 3.2 × 10(-15) - 5.6 × 10(-17)). These associations were independent of previously reported 2q35 variants, rs13387042/rs4442975 and rs16857609, and were stronger for ER-positive than ER-negative disease. Together, these results suggest that 2q35 breast cancer risk loci may be mediating their effect through IGFBP5.<br/>

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
Related URLs:
PubMed ID: 27402876
Web of Science ID: 393181300017


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item